Skip to main content
TrimSoMoEverything GLP-1, in one place
← All medications

FDA-approved medication

Wegovy Tablets (oral semaglutide)

Key facts

Last reviewed: 2026-11-06
  • •FDA label says "WEGOVY (semaglutide) tablets, for oral use".
  • •FDA label says "Take WEGOVY tablets orally once-daily on an empty stomach in the morning with water (up to 4 ounces). Do not take with other liquids besides water."
  • •FDA label says "Swallow tablets whole. Do not split, crush, chew or dissolve."
  • •FDA label says "WEGOVY tablets are indicated in combination with a reduced calorie diet and increased physical activity: • to reduce the risk of major adverse CV events (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established CV disease and either obesity or overweight. ( 1 ) • to reduce excess body weight and maintain weight reduction long term in adults with obesity, or in adults with overweight in the presence of at least one weight-related comorbid condition."

FDA-approved to reduce excess body weight and maintain weight reduction long term. Read the dose schedule and safety information, and check the official prescribing information. Confirm costs and coverage with your pharmacy, insurer, or the manufacturer.

oral semaglutide · 1.5 mg, 4 mg, 9 mg, and 25 mg tablets · once daily (morning, empty stomach)

Active ingredient
oral semaglutide
Dosage form (label)
Oral: 1.5 mg, 4 mg, 9 mg, and 25 mg tablets
Schedule (label)
Once daily (morning, empty stomach)
Strengths (label)
Tablets: 1.5 mg, 4 mg, 9 mg, and 25 mg. Take in the morning on an empty stomach with up to 4 ounces of plain water at least 30 minutes before first food, beverage, or other oral medications of the day.DailyMed FDA Prescribing Information (NDA 218316) · Wegovy official website. Accessed November 6, 2026.
Manufacturer
Novo Nordisk A/S (per label)

Brand names are trademarks of their respective owners; this site is not affiliated with them.

Illustration of a single round tablet on a clay saucer beside an opaque cup and a blank calendar card

FDA label

Wegovy Tablets dose steps (FDA label)

  1. 1.5 mg
    Days 1–30
    Starting dose
  2. 4 mg
    Days 31–60
    Dose escalation
  3. 9 mg
    Days 61–90
    Dose escalation
  4. 25 mg
    Day 91 & onward
    Maintenance dose
Per FDA label. Your prescriber sets your dose. Take WEGOVY tablets orally once-daily on an empty stomach in the morning with water (up to 4 ounces). Swallow tablets whole; do not split, crush, chew or dissolve. After taking WEGOVY tablet wait at least 30 minutes before eating food, drinking beverages or taking other oral medications. Recommended maintenance dosage is 25 mg orally once daily.

FDA label answers

Common questions about Wegovy Tablets

All answers are taken directly from the official FDA prescribing information (FDA Prescribing Information (DailyMed setid ee06186f-2aa3-4990-a760-757579d8f77b, SPL version 19, revised 06/2026)).

Who are Wegovy Tablets approved for?

FDA label says "WEGOVY tablets are indicated in combination with a reduced calorie diet and increased physical activity: • to reduce the risk of major adverse CV events (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established CV disease and either obesity or overweight. ( 1 ) • to reduce excess body weight and maintain weight reduction long term in adults with obesity, or in adults with overweight in the presence of at least one weight-related comorbid condition."

How often and when should Wegovy Tablets be taken?

FDA label says "Take WEGOVY tablets orally once-daily on an empty stomach in the morning with water (up to 4 ounces). Do not take with other liquids besides water."

What are the most common side effects listed on the label for Wegovy Tablets?

FDA label says "Most common adverse reactions (incidence ≥5%) in adults or pediatric patients aged 12 years and older are: nausea, diarrhea, vomiting, constipation, abdominal pain, dysesthesia, headache, fatigue, dyspepsia, dizziness, abdominal distension, eructation, hypoglycemia in patients with type 2 diabetes, flatulence, gastroenteritis, gastroesophageal reflux disease, and hair loss."

Is there a boxed warning on the Wegovy Tablets label?

Yes. FDA label says "WARNING: RISK OF THYROID C-CELL TUMORS" — "In rodents, semaglutide causes thyroid C-cell tumors at clinically relevant exposures."

What is the recommended dose escalation and maintenance for Wegovy Tablets?

FDA label says "Initiate WEGOVY tablet with a dosage of 1.5 mg once daily for 30 days. Then follow the dosage escalation schedule, titrating every 30 days to achieve the maintenance dosage. ( 2.2 ) • The recommended maintenance dosage of WEGOVY tablets is 25 mg orally once daily for cardiovascular risk reduction and weight reduction in adults."

Patient Consultation & Copay Protocol

Next Steps: Evaluating Wegovy Tablets for Your Care Plan

Transition from drug facts to clinical action. Estimate potential out-of-pocket expenses, generate consultation questions, and verify eligibility.

All Decision Tools
Copay & Savings Card

Out-of-Pocket Expense Modeling

Estimate what you might pay each month based on manufacturer assistance terms and employer benefit design.

Covered Commercial: Formulary tiering in development (aligns with peptide pricing paradigms)
Uncovered Commercial: Manufacturer copay programs expected upon broad commercial availability
Self-Pay Option: Institutional and retail pricing terms under development
Medicare: Medicare Part D weight loss coverage restrictions apply equally to oral formats
Clinical Readiness

Consultation & Lab Checklist

Arrive at your appointment prepared with essential baseline bloodwork requirements and contraindication screens.

Required Bloodwork: Baseline metabolic panels and strict morning fasting administration adherence
Safety Screening: Screening for personal/family history of MTC, MEN 2, pancreatitis, and gallbladder disease.
Clinical Format: Includes 12 essential lab panels and formatted physician questions.
Eligibility & Providers

BMI Qualification & Directory

Verify your body mass index against official FDA prescribing label requirements and locate qualified clinicians.

FDA Label Threshold: Chronic weight management under investigation and FDA approval criteria

Editorial & Regulatory Standard: TrimSoMo is an independent, non-commercial healthcare information platform. Estimated out-of-pocket costs and savings card parameters reflect publicly published 2026 manufacturer program guidelines and do not guarantee individual insurance coverage or pharmacy dispensing prices. Prescriptions require clinical evaluation by a licensed physician.

Before Starting Wegovy Tablets

Gradual Dose Titration

Per the FDA label, doses start low and increase over several months to help reduce gastrointestinal side effects. Your clinician sets your schedule. Review post-marketing data in our GLP-1 side effects from FDA labels → FAERS reports do not prove cause.

Lifestyle & Nutrition Support

In clinical studies, medication was used together with a reduced-calorie diet and increased physical activity.

Long-Term Plan

Talk with your clinician before changing or stopping treatment.

Future Pharmacotherapy Outlook

Exploring non-injectable options?

Some oral GLP-1 medicines are FDA-approved and others are still in development. The list shows each medicine's status and source.

Oral GLP-1 medicines: see which are FDA-approved and which are still in development →